FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022686977> ?p ?o ?g. }

• W2022686977 endingPage "2102" @default.
• W2022686977 startingPage "2094" @default.
• W2022686977 abstract "To assess the treatment outcome benefit of multiagent consolidation in young adults with acute myeloid leukemia (AML) in a prospective, randomized, multicenter trial.Between December 2003 and November 2009, 1,179 patients (median age, 48 years; range, 16 to 60 years) with untreated AML were randomly assigned at diagnosis to receive either standard high-dose cytarabine consolidation with three cycles of 18 g/m(2) (3× HD-AraC) or multiagent consolidation with two cycles of mitoxantrone (30 mg/m(2)) plus cytarabine (12 g/m(2)) and one cycle of amsacrine (500 mg/m(2)) plus cytarabine (10 g/m(2); MAC/MAMAC/MAC). Allogeneic and autologous hematopoietic stem-cell transplantations were performed in a risk-adapted and priority-based manner.After double induction therapy using a 3 + 7 regimen including standard-dose cytarabine and daunorubicin, complete remission was achieved in 65% of patients. In the primary efficacy population of patients evaluable for consolidation outcomes, consolidation with either 3× HD-AraC or MAC/MAMC/MAC did not result in any significant difference in 3-year overall (69% v 64%; P = .18) or disease-free survival (46% v 48%; P = .99) according to the intention-to-treat analysis. Furthermore, MAC/MAMAC/MAC led to additional GI and hepatic toxicity and a higher rate of infection and bleeding, resulting in significantly shorter 3-year overall survival in the per-protocol analysis compared with 3× HD-AraC (63% v 72%; P = .04).In younger adults with AML, multiagent consolidation using mitoxantrone and amsacrine in combination with high-dose cytarabine does not improve treatment outcome and confers additional toxicity." @default.
• W2022686977 created "2016-06-24" @default.
• W2022686977 creator A5002498295 @default.
• W2022686977 creator A5004741011 @default.
• W2022686977 creator A5006122560 @default.
• W2022686977 creator A5007449495 @default.
• W2022686977 creator A5010287150 @default.
• W2022686977 creator A5016360607 @default.
• W2022686977 creator A5017002895 @default.
• W2022686977 creator A5018356664 @default.
• W2022686977 creator A5023523782 @default.
• W2022686977 creator A5025105470 @default.
• W2022686977 creator A5026359397 @default.
• W2022686977 creator A5026849709 @default.
• W2022686977 creator A5035426042 @default.
• W2022686977 creator A5042951988 @default.
• W2022686977 creator A5045850647 @default.
• W2022686977 creator A5047674033 @default.
• W2022686977 creator A5047829491 @default.
• W2022686977 creator A5048469868 @default.
• W2022686977 creator A5054654885 @default.
• W2022686977 creator A5061229750 @default.
• W2022686977 creator A5067574718 @default.
• W2022686977 creator A5086016311 @default.
• W2022686977 date "2013-06-10" @default.
• W2022686977 modified "2023-10-18" @default.
• W2022686977 title "High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial" @default.
• W2022686977 cites W1965584494 @default.
• W2022686977 cites W1969545468 @default.
• W2022686977 cites W1973248441 @default.
• W2022686977 cites W2066915026 @default.
• W2022686977 cites W2072940754 @default.
• W2022686977 cites W2105573850 @default.
• W2022686977 cites W2116085973 @default.
• W2022686977 cites W2116858301 @default.
• W2022686977 cites W2118428391 @default.
• W2022686977 cites W2124433362 @default.
• W2022686977 cites W2127568389 @default.
• W2022686977 cites W2132912591 @default.
• W2022686977 cites W2134350774 @default.
• W2022686977 cites W2141034604 @default.
• W2022686977 cites W2144274033 @default.
• W2022686977 cites W2148841241 @default.
• W2022686977 cites W2150579113 @default.
• W2022686977 cites W2153994826 @default.
• W2022686977 cites W2156689952 @default.
• W2022686977 cites W2159507916 @default.
• W2022686977 cites W2159875685 @default.
• W2022686977 cites W2160746673 @default.
• W2022686977 cites W2315152253 @default.
• W2022686977 cites W2318674152 @default.
• W2022686977 cites W4237785786 @default.
• W2022686977 cites W4376595466 @default.
• W2022686977 doi "https://doi.org/10.1200/jco.2012.46.4743" @default.
• W2022686977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23630210" @default.
• W2022686977 hasPublicationYear "2013" @default.
• W2022686977 type Work @default.
• W2022686977 sameAs 2022686977 @default.
• W2022686977 citedByCount "65" @default.
• W2022686977 countsByYear W20226869772013 @default.
• W2022686977 countsByYear W20226869772014 @default.
• W2022686977 countsByYear W20226869772015 @default.
• W2022686977 countsByYear W20226869772016 @default.
• W2022686977 countsByYear W20226869772017 @default.
• W2022686977 countsByYear W20226869772018 @default.
• W2022686977 countsByYear W20226869772019 @default.
• W2022686977 countsByYear W20226869772020 @default.
• W2022686977 countsByYear W20226869772021 @default.
• W2022686977 countsByYear W20226869772022 @default.
• W2022686977 countsByYear W20226869772023 @default.
• W2022686977 crossrefType "journal-article" @default.
• W2022686977 hasAuthorship W2022686977A5002498295 @default.
• W2022686977 hasAuthorship W2022686977A5004741011 @default.
• W2022686977 hasAuthorship W2022686977A5006122560 @default.
• W2022686977 hasAuthorship W2022686977A5007449495 @default.
• W2022686977 hasAuthorship W2022686977A5010287150 @default.
• W2022686977 hasAuthorship W2022686977A5016360607 @default.
• W2022686977 hasAuthorship W2022686977A5017002895 @default.
• W2022686977 hasAuthorship W2022686977A5018356664 @default.
• W2022686977 hasAuthorship W2022686977A5023523782 @default.
• W2022686977 hasAuthorship W2022686977A5025105470 @default.
• W2022686977 hasAuthorship W2022686977A5026359397 @default.
• W2022686977 hasAuthorship W2022686977A5026849709 @default.
• W2022686977 hasAuthorship W2022686977A5035426042 @default.
• W2022686977 hasAuthorship W2022686977A5042951988 @default.
• W2022686977 hasAuthorship W2022686977A5045850647 @default.
• W2022686977 hasAuthorship W2022686977A5047674033 @default.
• W2022686977 hasAuthorship W2022686977A5047829491 @default.
• W2022686977 hasAuthorship W2022686977A5048469868 @default.
• W2022686977 hasAuthorship W2022686977A5054654885 @default.
• W2022686977 hasAuthorship W2022686977A5061229750 @default.
• W2022686977 hasAuthorship W2022686977A5067574718 @default.
• W2022686977 hasAuthorship W2022686977A5086016311 @default.
• W2022686977 hasBestOaLocation W20226869771 @default.
• W2022686977 hasConcept C126322002 @default.
• W2022686977 hasConcept C141071460 @default.
• W2022686977 hasConcept C143998085 @default.
• W2022686977 hasConcept C2776694085 @default.

• next